• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

IMPAACT 2010/VESTED RCT: What is the Optimal HIV Treatment During Pregnancy?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Lockman et al. (The Lancet, 2021) compared the safety and efficacy of three antiretroviral regimens started in pregnancy

METHODS:

  • Multicenter, open-label, randomized controlled, phase 3 trial
    • This International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 2010/Virologic Efficacy and Safety of ART Combinations with TAF/TDF, EFV, and DTG (VESTED) study
  • Participants
    • Pregnant women ≥18 years
    • Confirmed HIV-1 infection
    • 14 to 28 weeks gestation
    • Excluded:  History of previous antiretroviral use | Up to 14 days of antiretroviral therapy during the current pregnancy was permitted
  • Interventions
    • Treatment A: Once-daily oral dolutegravir 50 mg | Once-daily oral fixed-dose combination emtricitabine 200 mg and tenofovir alafenamide fumarate 25 mg
    • Treatment B: Once-daily oral dolutegravir 50 mg | Once-daily oral fixed-dose combination emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg
    • Treatment C: Once-daily oral fixed-dose combination of efavirenz 600 mg, emtricitabine 200 mg, and tenofovir disoproxil fumarate 300 mg
  • Study design
    • Randomized 1:1:1
    • Stratified by gestational age (14 to 18, 19 to 23, and 24 to 28 weeks gestation) and country
  • Primary efficacy outcome
    • The proportion of participants with viral suppression
      • HIV-1 RNA concentration <200 copies per mL, at or within 14 days of delivery
  • Primary safety outcomes
    • Composite adverse pregnancy outcome: Preterm delivery | SGA | Stillbirth | Spontaneous abortion
    • Occurrence of serious maternal and infant adverse events

RESULTS:

  • Treatment A: 217 women | Treatment B: 215 | Treatment C: 211
    • Median gestational age at enrollment: 21.9 weeks (IQR 18.3 to 25.3)
    • Median HIV-1 RNA concentration: 902.5 copies per mL (152.0 to 5182.5)
      • HIV-1 RNA concentrations of <200 copies per mL: 28% of participants
    • Median CD4 count: 466 cells per μL (308 to 624)
  • More patients in treatment groups A and B had viral suppression at delivery vs group C
    • Treatments A and B: 98% had suppression
    • Treatment C: 91% had suppression
    • Estimated difference 6.5% (95% CI, 2.0 to 10.7); P = 0.0052
  • Significantly fewer participants in the treatment group A had a composite adverse pregnancy outcome vs treatment groups B or C
    • Treatment B
      • Treatment A: 24%
      • Treatment B: 33%
      • Estimated difference −8.8% (95% CI, −17.3 to −0.3); P = 0.043
    • Treatment C
      • Treatment C: 33%
      • Estimated difference −8.6% (95% CI, –17.1 to −0.1); P = 0.047
  • The proportion of participants or infants with grade 3 or higher adverse events did not differ among the three groups
  • The proportion of participants who had a preterm delivery was significantly lower in the treatment A group than the treatment C group
    • Treatment A: 6%
    • Treatment C: 12%
    • Estimated difference −6.3% (95% CI, –11.8 to −0.9); P = 0.023
  • Neonatal mortality was significantly higher in the treatment C group than in either
    • Treatment A
      • Treatment C: 5%
      • Treatment A: 1%
      • P = 0.019
    • Treatment B
      • Treatment B: 2%
      • P = 0.050

CONCLUSION:

  • When antiretroviral therapy was started in pregnancy, treatments containing dolutegravir (A and B) resulted in better viral suppression than a combination of efavirenz, emtricitabine, and tenofovir disoproxil fumarate (C)
  • The dolutegravir, emtricitabine, and tenofovir alafenamide fumarate regimen (A) had the lowest frequency of adverse pregnancy outcomes and neonatal deaths
  • The authors conclude

When started at 14–28 weeks of pregnancy, all three ART regimens studied in this trial led to high rates of virological suppression

…the results of this trial showed that the efficacy and safety of dolutegravir-containing ART regimens observed in non-pregnant adults are also evident when started in pregnancy

These findings affirm the WHO recommendation to use dolutegravir in all populations, including in pregnant women, and suggest that dolutegravir, emtricitabine, and tenofovir alafenamide fumarate might be preferred

Learn More – Primary Sources:

Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

CDC Guidelines on Antiretroviral Preexposure Prophylaxis to Prevent HIV in Those at Risk
Does Amniocentesis or CVS Increase the risk of HIV Vertical Transmission?
Can Different Dosing Regimens Increase Effectiveness of the Flu Vaccine for Women Living with HIV?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site